Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

Hanae Nakashima, Takeshi Ishihara, Pilar Suguimoto, Osamu Yokota, Etsuko Oshima, Aki Kugo, Seishi Terada, Takashi Hamamura, John Q. Trojanowski, Virginia M Y Lee, Shigetoshi Kuroda

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Lithium, a widely used drug for treating affective disorders, is known to inhibit glycogen synthase kinase-3 (GSK-3), which is one of the major tau kinases. Thus, lithium could have therapeutic benefit in neurodegenerative tauopathies by reducing tau hyperphosphorylation. We tested this hypothesis and showed that long-term administration of lithium at relatively low therapeutic concentrations to transgenic mice that recapitulate Alzheimer's disease (AD)-like tau pathologies reduces tau lesions, primarily by promoting their ubiquitination rather than by inhibiting tau phosphorylation. These findings suggest novel mechanisms whereby lithium treatment could ameliorate tauopathies including AD. Because lithium also has been shown to reduce the burden of amyloid-β pathologies, it is plausible that lithium could reduce the formation of both amyloid plaques and tau tangles, the two pathological hallmarks of AD, and thereby ameliorate the behavioral deficits in AD.

Original languageEnglish
Pages (from-to)547-556
Number of pages10
JournalActa Neuropathologica
Volume110
Issue number6
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Tauopathies
Ubiquitination
Lithium
Alzheimer Disease
Pathology
Glycogen Synthase Kinase 3
Amyloid Plaques
Mood Disorders
Amyloid
Transgenic Mice
Phosphotransferases
Phosphorylation
Therapeutics
Pharmaceutical Preparations

Keywords

  • Animal models
  • GSK-3
  • Lithium
  • Tau
  • Ubiquitination

ASJC Scopus subject areas

  • Clinical Neurology
  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Nakashima, H., Ishihara, T., Suguimoto, P., Yokota, O., Oshima, E., Kugo, A., ... Kuroda, S. (2005). Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathologica, 110(6), 547-556. https://doi.org/10.1007/s00401-005-1087-4

Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. / Nakashima, Hanae; Ishihara, Takeshi; Suguimoto, Pilar; Yokota, Osamu; Oshima, Etsuko; Kugo, Aki; Terada, Seishi; Hamamura, Takashi; Trojanowski, John Q.; Lee, Virginia M Y; Kuroda, Shigetoshi.

In: Acta Neuropathologica, Vol. 110, No. 6, 12.2005, p. 547-556.

Research output: Contribution to journalArticle

Nakashima, H, Ishihara, T, Suguimoto, P, Yokota, O, Oshima, E, Kugo, A, Terada, S, Hamamura, T, Trojanowski, JQ, Lee, VMY & Kuroda, S 2005, 'Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies', Acta Neuropathologica, vol. 110, no. 6, pp. 547-556. https://doi.org/10.1007/s00401-005-1087-4
Nakashima, Hanae ; Ishihara, Takeshi ; Suguimoto, Pilar ; Yokota, Osamu ; Oshima, Etsuko ; Kugo, Aki ; Terada, Seishi ; Hamamura, Takashi ; Trojanowski, John Q. ; Lee, Virginia M Y ; Kuroda, Shigetoshi. / Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. In: Acta Neuropathologica. 2005 ; Vol. 110, No. 6. pp. 547-556.
@article{cdd9c4989486441ba40b7ffd32858d72,
title = "Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies",
abstract = "Lithium, a widely used drug for treating affective disorders, is known to inhibit glycogen synthase kinase-3 (GSK-3), which is one of the major tau kinases. Thus, lithium could have therapeutic benefit in neurodegenerative tauopathies by reducing tau hyperphosphorylation. We tested this hypothesis and showed that long-term administration of lithium at relatively low therapeutic concentrations to transgenic mice that recapitulate Alzheimer's disease (AD)-like tau pathologies reduces tau lesions, primarily by promoting their ubiquitination rather than by inhibiting tau phosphorylation. These findings suggest novel mechanisms whereby lithium treatment could ameliorate tauopathies including AD. Because lithium also has been shown to reduce the burden of amyloid-β pathologies, it is plausible that lithium could reduce the formation of both amyloid plaques and tau tangles, the two pathological hallmarks of AD, and thereby ameliorate the behavioral deficits in AD.",
keywords = "Animal models, GSK-3, Lithium, Tau, Ubiquitination",
author = "Hanae Nakashima and Takeshi Ishihara and Pilar Suguimoto and Osamu Yokota and Etsuko Oshima and Aki Kugo and Seishi Terada and Takashi Hamamura and Trojanowski, {John Q.} and Lee, {Virginia M Y} and Shigetoshi Kuroda",
year = "2005",
month = "12",
doi = "10.1007/s00401-005-1087-4",
language = "English",
volume = "110",
pages = "547--556",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

AU - Nakashima, Hanae

AU - Ishihara, Takeshi

AU - Suguimoto, Pilar

AU - Yokota, Osamu

AU - Oshima, Etsuko

AU - Kugo, Aki

AU - Terada, Seishi

AU - Hamamura, Takashi

AU - Trojanowski, John Q.

AU - Lee, Virginia M Y

AU - Kuroda, Shigetoshi

PY - 2005/12

Y1 - 2005/12

N2 - Lithium, a widely used drug for treating affective disorders, is known to inhibit glycogen synthase kinase-3 (GSK-3), which is one of the major tau kinases. Thus, lithium could have therapeutic benefit in neurodegenerative tauopathies by reducing tau hyperphosphorylation. We tested this hypothesis and showed that long-term administration of lithium at relatively low therapeutic concentrations to transgenic mice that recapitulate Alzheimer's disease (AD)-like tau pathologies reduces tau lesions, primarily by promoting their ubiquitination rather than by inhibiting tau phosphorylation. These findings suggest novel mechanisms whereby lithium treatment could ameliorate tauopathies including AD. Because lithium also has been shown to reduce the burden of amyloid-β pathologies, it is plausible that lithium could reduce the formation of both amyloid plaques and tau tangles, the two pathological hallmarks of AD, and thereby ameliorate the behavioral deficits in AD.

AB - Lithium, a widely used drug for treating affective disorders, is known to inhibit glycogen synthase kinase-3 (GSK-3), which is one of the major tau kinases. Thus, lithium could have therapeutic benefit in neurodegenerative tauopathies by reducing tau hyperphosphorylation. We tested this hypothesis and showed that long-term administration of lithium at relatively low therapeutic concentrations to transgenic mice that recapitulate Alzheimer's disease (AD)-like tau pathologies reduces tau lesions, primarily by promoting their ubiquitination rather than by inhibiting tau phosphorylation. These findings suggest novel mechanisms whereby lithium treatment could ameliorate tauopathies including AD. Because lithium also has been shown to reduce the burden of amyloid-β pathologies, it is plausible that lithium could reduce the formation of both amyloid plaques and tau tangles, the two pathological hallmarks of AD, and thereby ameliorate the behavioral deficits in AD.

KW - Animal models

KW - GSK-3

KW - Lithium

KW - Tau

KW - Ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=28844481487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844481487&partnerID=8YFLogxK

U2 - 10.1007/s00401-005-1087-4

DO - 10.1007/s00401-005-1087-4

M3 - Article

VL - 110

SP - 547

EP - 556

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 6

ER -